IL2 and pancreatic neoplasm: Notably, the PANCEP-1 trial, evaluating peri- and postoperative treatment with histamine dihydrochloride (HDC) and low-dose IL-2 in patients with primary resectable pancreatic cancer, has recently been initiated.